Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias

BACKGROUND: Resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia (CML) and Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph-positive ALL) is frequently caused by mutations in the BCR-ABL kinase domain. Ponatinib (AP24534) is a potent oral tyrosine kinas...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Cortes, Jorge E., Kantarjian, Hagop, Shah, Neil P., Bixby, Dale, Mauro, Michael J., Flinn, Ian, O'Hare, Thomas, Hu, Simin, Narasimhan, Narayana I., Rivera, Victor M., Clackson, Tim, Turner, Christopher D., Haluska, Frank G., Druker, Brian J., Deininger, Michael W.N., Talpaz, Moshe
Formato: Artigo
Idioma:Inglês
Publicado em: 2012
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3777383/
https://ncbi.nlm.nih.gov/pubmed/23190221
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1205127
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados